Modality
Degrader
MOA
JAK1/2i
Target
BTK
Pathway
RAS/MAPK
CRC
Development Pipeline
Preclinical
~Mar 2017
→ ~Jun 2018
Phase 1
~Sep 2018
→ ~Dec 2019
Phase 2
~Mar 2020
→ ~Jun 2021
Phase 3
~Sep 2021
→ ~Dec 2022
NDA/BLA
~Mar 2023
→ ~Jun 2024
Approved
Sep 2024
→ Nov 2029
ApprovedCurrent
NCT07977609
243 pts·CRC
2024-09→2029-11·Completed
243 total pts1 indication
CompletedCurrentUpcoming
Catalysts (1)
2029-11-283.7y awayPh3 Readout· CRC
Trial Timeline
Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q4
Approved
Complet…
Catalysts
Ph3 Readout
2029-11-28 · 3.7y away
CRC
Completed|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07977609 | Approved | CRC | Completed | 243 | VA |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-5501 | Pfizer | Phase 1 | BTK | |
| RHH-8482 | Roche | Phase 1 | BTK | |
| Fixanesiran | AbbVie | Preclinical | RET | |
| Zorizanubrutinib | Novo Nordisk | Phase 1 | BTK | |
| Motavorutinib | Amgen | Phase 3 | CDK4/6 | |
| VRT-9481 | Vertex Pharma | Phase 1/2 | Menin | |
| Sovarelsin | BioMarin | Phase 2 | CFTR | |
| Peminaritide | Sarepta | NDA/BLA | PLK4 | |
| 369-8021 | Hansoh Pharma | Approved | BTK | |
| Niramavacamten | Hansoh Pharma | Phase 2 | SGLT2 |